This NCR Healthcare Stock Rises 38% in 1 Year: Beds, Occupancy and the Apollo Tyres Link

This NCR healthcare stock has risen approximately 38% in twelve months, closing at Rs 331.90 on 17 September 2026 against Rs 241.04 a year earlier. That ranks it among the stronger names on a screen of NSE small-cap stocks by 1-year return, dated 17 September.

The company is Artemis Medicare Services Ltd (NSE: ARTEMISMED), the Gurugram hospital operator promoted by the family behind Apollo Tyres. Almost all its revenue comes from one 541-bed campus, and this NCR healthcare stock has rallied on a plan to change that, targeting 2,000 operational beds by FY30.

Click Here – Get Free Investment Predictions

How Much Has This NCR Healthcare Stock Returned in One Year?

This NCR healthcare stock returned approximately 37.7% from 17 September 2025 to 17 September 2026 on a close-to-close basis, from Rs 241.04 to Rs 331.90. It fell to Rs 203.35 on 30 March 2026 and hit a record Rs 362.00 on 10 September 2026.

Longer periods look bigger for this NCR healthcare stock. All figures use closing prices, nearest trading day where a date was a holiday.

Period	Start date	Start close	Price return
1 Month	17 Aug 2026	Rs 314.40	5.6%
6 Months	17 Mar 2026	Rs 222.40	49.2%
1 Year	17 Sep 2025	Rs 241.04	37.7%
3 Years	15 Sep 2023	Rs 135.15	145.6%
5 Years	17 Sep 2021	Rs 37.98	774.0%

This NCR healthcare stock lost about 16% between mid-January and end-March 2026, and nearly the whole annual gain arrived after April. A six-month return larger than the one-year figure says the re-rating is recent.

Why This NCR Healthcare Stock Rose 38% in a Year

Q2 FY26 Results on 11 November 2025 Started the Re-Rating

On 11 November 2025 September-quarter revenue came in at Rs 274.70 crore, up 13.8%, EBITDA at Rs 58.27 crore on a 21.2% margin and net profit up 35.6% to Rs 30.00 crore. Occupancy was 64.1%, revenue per occupied bed Rs 81,248. The NCR healthcare stock rose 6.8% next session on ten times normal volume and never traded back at pre-result levels.

The VIMHANS Agreement on 20 February 2026 Added 650 Beds in South Delhi

On 20 February 2026 the company won long-term exclusive rights to operate the VIMHANS campus at Nehru Nagar in south Delhi, a 3.5-acre site with roughly 7 lakh square feet of built-up area and capacity above 650 beds. Under the medical services agreement the land stays with the trust while the company funds construction through an interest-free advance. Planned spend is Rs 500 crore to Rs 520 crore in two phases, roughly Rs 75 lakh to Rs 80 lakh per bed, the biggest change in the history of this NCR healthcare stock.

A Rs 700 Crore Fund Raise Was Approved for the Pipeline

On 3 March 2026 the board took up a Rs 700 crore qualified institutional placement, cleared by shareholders in July on 98.68% approval. The three-year capital plan is around Rs 800 crore: Rs 120 crore for Raipur, Rs 350 crore to Rs 360 crore for phase one in south Delhi and Rs 120 crore for the Gurugram tower. Net debt is guided near Rs 250 crore to Rs 280 crore, which kept the NCR healthcare stock bid through March.

Raipur Opened in July 2026 and Q1 FY27 Beat on Margins

The 300-bed Artemis Shanti Hospital in Raipur opened on 9 July 2026, the first material asset outside Delhi-NCR. June-quarter results on 3 August 2026 showed revenue of Rs 287.32 crore, up 12.7%, EBITDA up 27.9% to Rs 61.82 crore and net profit up 48.3% to Rs 31.44 crore. The NCR healthcare stock gained 6.8% on 5 August and another 10% by early September.

Artemis Medicare Share Price and the Financials Behind It

The record behind the Artemis Medicare share price is far better than three years ago. Revenue compounded from Rs 558.70 crore in FY22 to Rs 1,111.07 crore in FY26 and net profit from Rs 31.40 crore to Rs 103.72 crore, with operating margin widening from 12.86% to 19.88%. That is the earnings base under this NCR healthcare stock.

Quarterly trends matter more for a NCR healthcare stock in expansion mode, because margins track occupancy quarter to quarter.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Net profit (Rs Cr)	Operating margin	Net margin
Jun 2025	261.89	48.33	21.20	18.95%	8.35%
Sep 2025	282.35	58.27	30.00	21.21%	10.91%
Dec 2025	279.81	52.03	22.23	17.97%	9.05%
Mar 2026	287.02	59.39	30.28	21.27%	10.75%
Jun 2026	292.69	61.82	31.44	21.52%	10.90%

December 2025 was the soft quarter, margin dipping to 17.97%. It has since climbed twice to 21.52%, the best in the set. Trailing earnings per share for this NCR healthcare stock is Rs 7.20 against book value of Rs 54.69.

Debt to equity has fallen from 0.85 in FY24 to 0.28, helped by equity from a development institution. FY26 operating cash flow of Rs 131.95 crore against capital expenditure of Rs 104.95 crore covers maintenance but not the pipeline. That gap is what the placement is for, and why this NCR healthcare stock reacts to fund-raise news.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Beds, Occupancy and ARPOB: Three Numbers That Drive This NCR Healthcare Stock

Hospital equities move on bed count, how full they are and what each occupied bed earns per day. This NCR healthcare stock ran more than 800 beds in late 2025, anchored by the 541-bed Gurugram campus plus Artemis Lite and Daffodils units. Raipur adds 300 and south Delhi more than 650. A new Gurugram tower is planned at 130 to 150 beds for Rs 120 crore, with breakeven guided within 8 to 10 months because it sits on land the group controls.

Occupancy of 65.7% against 61.2% a year earlier is progress but short of mature Indian chains. Each point gained on an existing asset drops almost entirely into EBITDA, which is how this NCR healthcare stock expanded margin 250 basis points without a large revenue jump.

ARPOB of Rs 85,690 against Rs 79,752 is a 7.4% rise, driven by a richer mix of cardiology, oncology, neurosciences and orthopaedics rather than price increases. International patients gave Rs 76.51 crore last quarter, 27.5% of hospital revenue, down from 32%.

The Apollo Tyres Promoter Link Behind This NCR Healthcare Stock

This NCR healthcare stock shares its promoter family with Apollo Tyres. Onkar Kanwar, chairman of Apollo Tyres, chairs it too, and Neeraj Kanwar plus Apollo Tyres Ltd sit inside the promoter group. Constructive Finance Private Limited holds 58.38% and managing director Dr Devlina Chakravarty 2.92%.

That link cuts both ways. It supplied patient capital through a long build-out, but minority holders of the NCR healthcare stock depend on one family allocating across two unrelated businesses.

Shareholding in the NCR healthcare stock also shifted sharply during the period under review.

Quarter	Promoters	FII	DII	Public
Sep 2025	66.53%	0.37%	4.27%	28.83%
Nov 2025	58.43%	12.48%	3.35%	25.75%
Dec 2025	58.39%	12.47%	2.91%	26.24%
Mar 2026	58.39%	12.19%	2.89%	26.53%
Jun 2026	58.39%	12.29%	2.40%	26.92%

Foreign holding jumped from 0.37% to 12.48% between September and November 2025, with a World Bank Group development institution at 11.98% after a Rs 330 crore investment. Promoter holding eased to 58.39% while domestic institutions trimmed from 4.27% to 2.40%, so this NCR healthcare stock is not seeing broad institutional accumulation.

Risks in This NCR Healthcare Stock

The risks in this NCR healthcare stock are specific, and several are live now.

Single-asset concentration. Gurugram delivered Rs 278.49 crore of the Rs 287.32 crore consolidated June-quarter revenue. Any disruption there hits nearly the whole business. Until Raipur and south Delhi scale, this NCR healthcare stock is a one-hospital company on a network valuation.

Execution and start-up losses. Management has guided to roughly Rs 20 crore of operating losses at Raipur before breakeven in 15 to 18 months. South Delhi sits on land the company does not own, so delays, overruns or a dispute would be costly for the NCR healthcare stock.

Dilution and valuation. A Rs 700 crore placement against market capitalisation near Rs 5,163 crore is real dilution. This NCR healthcare stock trades at a trailing PE of 45.30 on return on equity of 11.09%, so investors are paying for beds that do not yet exist.

Liquidity and volatility. A Rs 5,163 crore market capitalisation and no listed derivatives make exits slow in a fall. This NCR healthcare stock ranged from Rs 203.35 to Rs 362.00 inside twelve months and fell roughly 9% across 15 and 16 September 2026 before recovering 2%. Volumes swing from under one lakh shares to over twenty lakh around events.

Pledge history and patient mix. Promoter shares were substantially pledged until the June 2025 quarter, when the pledge was released in full, so check this disclosure each quarter rather than assume zero. Over a quarter of hospital revenue comes from international patients, exposing the NCR healthcare stock to visa policy, currency and geopolitics.

Download the Univest iOS App or Univest Android App to track the Artemis Medicare share price live

Artemis Medicare Share: Analyst View

Coverage of this NCR healthcare stock is thin. One domestic brokerage published a note on 4 August 2026 with an ADD rating, assuming compounded revenue growth of 29.4% and profit growth of 33.3% over FY26 to FY29.

Artemis Medicare Share Price Target

The only verified Artemis Medicare share price target on record is Rs 325, set by that brokerage on 4 August 2026 when the share traded near Rs 300. At Rs 331.90 it has passed that level. No higher Artemis Medicare share price target has appeared since, and one note is a weak signal, not a consensus.

Without a fresh target, the reference points are price levels and earnings. The 52-week high of Rs 362.00 sits 9% above the current price, the low of Rs 203.35 about 39% below. A PE of 45.30 against a sector average near 67.00 looks undemanding, but that average is lifted by far larger chains.

The honest reading is that this NCR healthcare stock already embeds delivery of the full bed pipeline. If occupancy climbs toward 70% and Raipur breaks even on time, multiples compress fast. If either slips, there is little support beneath the Artemis Medicare share price.

Other Stocks to Track From the Same Return Screen

Beyond this NCR healthcare stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Shivalik Bimetal with a 1-year return of 99.14%, RR Kabel at 93.99% and Chennai Petroleum at 91.97%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this NCR healthcare stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

A 38% gain on this NCR healthcare stock is a re-rating earned by operating progress: occupancy up 450 basis points, ARPOB up 7.4%, margin at a five-quarter high and profit up 48.3% last quarter. It is also a bet placed early on projects that contribute little before FY28.

The checklist is short: quarterly occupancy at Gurugram, the ramp at Raipur, terms of the Rs 700 crore placement, and whether south Delhi holds its Rs 520 crore budget. This NCR healthcare stock has priced in a good outcome on all four, so size positions accordingly and consult a SEBI-registered adviser.

Frequently Asked Questions

Which NCR healthcare stock rose 38% in one year?

Ans. Artemis Medicare Services Ltd (NSE: ARTEMISMED) is the NCR healthcare stock that gained approximately 37.7% between 17 September 2025 and 17 September 2026, from Rs 241.04 to Rs 331.90. It runs a 541-bed tertiary hospital in Gurugram and a 300-bed hospital in Raipur.

Why did the Artemis Medicare share price rise in 2026?

Ans. Operating gains plus a visible expansion pipeline drove it. Occupancy rose to 65.7% from 61.2% and ARPOB to Rs 85,690 from Rs 79,752, while the company took on a 650-bed south Delhi campus and approved a Rs 700 crore fund raise.

What were the Artemis Medicare Q1 FY27 results?

Ans. Revenue from operations was Rs 287.32 crore for the June 2026 quarter, up 12.7%, reported on 3 August 2026. EBITDA rose 27.9% to Rs 61.82 crore at a 21.5% margin and net profit 48.3% to Rs 31.44 crore, with diluted EPS of Rs 1.98.

What is the Artemis Medicare share price target?

Ans. The only verified Artemis Medicare share price target on record is Rs 325, published by a domestic brokerage on 4 August 2026 with an ADD rating. The share closed at Rs 331.90 on 17 September 2026, already above it, and no higher target has appeared since.

How is this NCR healthcare stock connected to Apollo Tyres?

Ans. Both share the same promoter family. Onkar Kanwar, chairman of Apollo Tyres, chairs Artemis Medicare, and Neeraj Kanwar and Apollo Tyres Ltd sit in the promoter group, with the main 58.38% holding routed through Constructive Finance Private Limited.

How many beds does Artemis Medicare operate and plan to add?

Ans. The group ran more than 800 beds in late 2025, anchored by 541 in Gurugram. It added 300 in Raipur in July 2026, plans 130 to 150 in a new Gurugram tower and 650 in south Delhi, targeting close to 2,000 operational beds by FY30.

What is the 52-week high and low of this NCR healthcare stock?

Ans. The 52-week high is Rs 362.00, touched on 10 September 2026, and the low is Rs 203.35 on 30 March 2026. At Rs 331.90 the share trades about 9% below its high and 63% above its low.

Is this NCR healthcare stock worth buying after a 38% rally?

Ans. That depends on tolerance for execution risk, since a PE near 45.30 prices in beds that are not yet operational. Positives are rising occupancy, profit up 48.3% and debt to equity of 0.28; risks are single-campus concentration, Raipur losses, dilution and thin liquidity.